Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Figures & data

Figure 1 Therapeutic strategies have been developed to target various steps in the PI3K/AKT/mTOR pathway, thereby blocking cell proliferation, growth and survival.

Note: Reprinted by permission from Springer Nature: Springer, Breast Cancer Res Treat, Costa, RLB, Han HS, and Gradishar WJ, Targeting the PI3K/AKT/mTOR pathway in triple negative breast cancer: a review. Copyright (2018). 169(3): p. 397–406. Available from: https://link.springer.com/article/10.1007/s10549-018-4697-y .²⁹

Table 1 Ongoing Clinical Trials Investigating Therapies Targeting the PI3K/AKT/mTOR Pathway

Therapy	PI3K-α	PI3K-β	PI3K-δ	PI3K-γ	AKT	mTOR	Trial ID	Study Phase
MEN1611 + Trastuzumab ±faslodex	x						NCT03767335	Ib
AZD8186 + docetaxel		x					NCT03218826	I
Alpelisib + faslodex or letrozole	x						NCT03056755	II
Alpelisib + nab-paclitaxel	x						NCT04216472	II
Gedatolisib + palbociclib + faslodex	x	x	x	x		x	NCT02626507	Ib
Gedatolisib + palbociclib/letrozole or palbociclib/faslodex	x	x	x	x		x	NCT02684032	Ib
Ipatasertib + faslodex Ipatasertib + aromatase inhibitor (AI) Ipatasertib + faslodex + palbociclib					x		NCT03959891	I
Ipatasertib + trastuzumab + pertuzumab + endocrine therapy (if HR+)					x		NCT04253561	Ib
Gedatolisib + PTK7-ADC	x	x	x	x		x	NCT03243331	I
PDR001 (PD1 monoclonal antibody) + everolimus, LCL161 or panobinostat						x	NCT02890069	Ib
AZD5363 + paclitaxel					x		NCT02423603	II
AZD2014 + olaparib						x	NCT02208375	Ib
AZD 5363 + olaparib					x		NCT02208375	Ib
AZD2014 + selumetinib (MEK inhibitor)						x	NCT02583542	Ib/II
Taselisib +enzalutamide	x		x	x			NCT02457910	Ib/II

CostaRLB, HanHS, GradisharWJ. Targeting the PI3K/AKT/mTOR pathway in triple negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397–406. doi:10.1007/s10549-018-4697-y29417298

 PubMed Web of Science ®Google Scholar